Certainly from the Health Canada side, part of the reason we rationalize this pathway is, very much to your point, that in hospitals we're seeing more and more abilities to fabricate products right at bedside; you'll genetically inform a cell and put it in a patient. You're right. This is something that is creating a more personalized lens.
Certainly from the safety regulations standpoint we want to make sure we're getting it right. We may not see the big clinical trials that we used to see. It may be a one-time therapy. That's pretty disruptive for us. Usually we see drugs given over time and can see how patients are doing.
Some of these new models are thus going to take some thinking, but that's why we have it so that we can tailor the requirements. We are making sure that we're keeping in touch with health technology assessors and others who are currently dealing with these types of therapies.